It is increasingly recognized that chronic rhinosinusitis (CRS) comprises a spectrum of different diseases with distinct clinical presentations and pathogenic mechanisms. Defining the distinct phenotypes and endotypes of CRS affects prognosis and, most importantly, is necessary as the basis for making therapeutic decisions. The need for individualized definitions of pathogenic mechanisms before initiating therapy extends to virtually all therapeutic considerations. This is clearly crucial with antibiotics, where, barring an influence from their off-target anti-inflammatory pharmacologic effects, an understanding of the role of the individual biome predicts likelihood of therapeutic benefit. However, this need for identifying individual phenotypes and endotypes also extends to the agent that is currently considered the mainstay of treatment of CRS, specifically glucocorticoids. As with asthma, it is recognized that a large minority of patients with CRS have a steroid-resistant phenotype, identification of which will preclude use of these agents with their potential side effects. Identification of endotypes is also becoming increasingly imperative because targeted biotherapeutic agents, such as anti-IgE and anticytokine antibodies, are becoming available. These agents are likely to benefit patients in whom the targeted mediator is not only expressed but demonstrably driving a central mechanism in that patient. In summary, the treatment of CRS is at an exciting crossroad. On the positive side, numerous therapeutics are in development that seem likely to have a positive effect in our patients with this condition. The challenge is that these therapies will require targeted individualized treatments based on identifying subjects with the relevant endotype. (J Allergy Clin Immunol 2017;140:1499-508.)
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Historically, chronic rhinosinusitis (CRS) was defined as any inflammatory condition of the paranasal sinuses and associated nasal mucosa that persisted for more than 12 weeks. 1, 2 However, it is increasingly recognized that CRS comprises a spectrum of conditions with distinct clinical presentations and pathogenic mechanisms. [3] [4] [5] Defining these distinct endotypes is more than an academic exercise because properly distinguishing different presentations of CRS affects prognosis and forms the basis for making therapeutic decisions. This latter consideration is becoming increasingly imperative as targeted biotherapeutic agents, such as anti-IgE and anti-cytokine antibodies, become available. These agents are most likely to benefit patients in whom the targeted mediator is not only expressed but also demonstrably driving a central mechanism in that patient.
Although this concept might seem self-evident with biologics, the need for individualized defining of pathogenic mechanisms before initiating therapy likely extends to virtually all therapeutic considerations. For example, this is also crucial with antibiotics, where, barring an influence from their off-target pharmacologic effects, an understanding of the role of the individual biome is certain to predict the likelihood of therapeutic benefit. However, this need for identifying individual phenotypes and endotypes also extends to the agent that is currently considered the mainstay of treatment of CRS, specifically corticosteroids. 1, 2 This is the most important of many questions currently unanswered in regards to understanding our approaches to understanding and treating CRS (Table I) .
bacteria, bacteria-derived antigens. Pathogen-associated molecular patterns and proinflammatory compounds that contribute to the presence and severity of inflammation may also gain access to submucosal tissue. Loss of epithelial barrier function reflects numerous inflammatory processes, including, most importantly, the metaplastic transformation of epithelial cells into goblet cells, a process mediated especially by IL-13, as occurs perhaps most importantly in the metaplastic transformation of epithelial cells into goblet cells as well as the more recently recognized process of epithelial mesenchymal transition. These processes mediated especially by IL-13 in the former and driven by numerous mediators but especially ascribed to amphiregulin and oncostatin M. 6 
Nasal polyposis
Although the need for defining individualized disease pathogenic mechanisms (ie, endotypes) seems apparent, what is less apparent is recognition of unambiguous, validated, and reasonably accessible biomarkers to define these disease types. Current recommendations phenotype CRS based on the presence (chronic rhinosinusitis with nasal polyps [CRSwNP]) or absence (chronic rhinosinusitis without nasal polyps [CRSsNP]) of nasal polyps (NPs). 1, 2 This is based on the observation that NP disease is more likely to be associated with an eosinophil-mediated T H 2-high (IL-4-, IL-5-, and IL-13-high) cytokine profile. In contrast, CRSsNP was thought to present as a noneosinophilic disease. This phenotyping approach remains valid, primarily based on the relative ease of endoscopically defining polyp status.
More recently, however, it has been recognized that NP status alone, although helpful, can often be inadequate for defining a T H 2-high/IL-5-high state. There are numerous exceptions to this concept, and these can become quite profound, especially based on regional differences. 7 In the study by Wang et al, 7 it was recognized that NPs in patients with CRS can be T H 2 low in between 15% and 80% of patients (Fig 1) , and similarly, anywhere from 20% to 75% of these subjects did not express a robust eosinophilia profile. In contrast, a significant subset (5% to 40%) of patients with CRSsNP displayed a T H -high/eosinophil-high profile. This increasing recognition that NPs alone cannot be used to distinguish an eosinophilic from a noneosinophilic presentation of CRS has been confirmed more recently. Tan et al 8 confirmed higher concentrations of IL-5 within the sinus mucosa of patients with CRSwNP compared with those with CRSsNP; however, there is a remarkable degree of overlap in the expression of these molecules between the 2 cohorts.
This problem of using NPs alone to define immune status becomes apparent when considering the endotype of cystic fibrosis (CF). The term endotype can be appropriately used for this disease because it is defined by the presence of mutations in a specific gene, CFTR. Yet when the phenotype of CF sinus disease is considered, it is recognized that these patients have polyps that run the spectrum of being paucigranulocytic, neutrophilic, eosinophilic, or mixed granulocytic. 9 This raises the intriguing question as to how any inflammatory insult in the sinuses, such as that generated by CF, can variously and seemingly randomly lead to potential ''switching on'' of a T H 2/eosinophilic process. Similar variable pathologic outcomes are also observed with other distinct CRS endotypes, such as those driven by common variable immune deficiency and primary ciliary dyskinesia.
The concept that a single genetic endotype can elicit numerous phenotypes could extend to all presentations of CRS, and this identifies yet another obstacle to defining endotypes. 10 To make this even more daunting, these observations raise the intriguing question as to whether any given phenotype is ''fixed'' or, as seems equally plausible, that any given phenotype (eg, eosinophilia) can evolve and resolve over time. An alternative example is whether a polyp might start with T H 1 inflammation and then evolve through T H 2 to T H 17 processes (with mixing in between).
Inflammatory cell profile (neutrophilic and eosinophilic CRS)
Because NPs can only at best approximate acting as a surrogate for assessing eosinophil status, an alternative approach is to specifically evaluate sinus tissue and quantify eosinophil expression. In the study by Tan et al, 8 however, not only was the presence of NPs inadequate in distinguishing a T H 2-high state, so was the presence of eosinophilia. Thus, using tissue concentrations of eosinophil cationic protein (ECP) as a surrogate marker for tissue eosinophilia, as with IL-5, although values were significantly greater in patients with CRSwNP, there was extensive overlap in ECP concentrations between patients with and without NPs. 8 It should be appreciated that the poor ability of ECP to distinguish CRS phenotypes might reflect its lack of complete specificity to the eosinophils, including its secretion by PMNs and basophils, at least in part.
MICROBIOME PHENOTYPES OF CRS
Evaluation of the microbiome is of particular interest in patients with CRS in that characterization of the microbial environment that gives rise to the disease process would seemingly allow for directed antimicrobial treatment measures. Multiple studies have now demonstrated that CRS involves dysbiosis of the microbiome, suggesting asymmetric diversity rather than overexpression of a predominant species as the culprit. 11, 12 Advances in bacterial detection with next-generation sequencing allow diagnostic methods that advance beyond current swab and culture techniques, although the ideal method by which to examine the microbiota of a given patient remains unclear. 13, 14 Other works have evaluated potential harmful changes that occur with antibiotic and anti-inflammatory treatments, which in general are paradoxically considered primary components in the medical treatment of CRS. 15 Collectively, these microbiome studies allow for consideration of new schema by which to approach patients with CRS similar to re-evaluations based on endotypes and immunologic profiles. Recently, Hoggard et al 12 demonstrated that microbiota dysbiosis was more likely to be observed between groups when patients were separated into clinical variants (ie, with or without asthma) rather than a predominant association between a specific pathogen and an associated phenotype or endotype. Specifically, patients with asthma and CF more strongly demonstrated decreased bacterial diversity and an overall increased bacterial load than patients without these comorbidities.
Cope et al 16 suggested distinct microbiota classifications that demonstrate or correlate with unique immunologic responses, functional attributes, and related risk of phenotypes, such as the presence or absence of polyps. As more is learned about the immunologic and inflammatory profiles of CRS, it seems certain that the interwoven effect of the microbiome will be elucidated further.
ENDOTYPING OF CRS
Theoretically, in the future, it might be possible to make clinically available the means of defining the inflammatory endotype based on microarray-based studies with detailed analyses of individual transcriptomic, proteomic, or one of the vast number of other ''omic'' signatures. At present, initial steps toward such approaches have been taken with detailed analyses of cytokine signatures associated with T H 1, T H 2, and T H 17 inflammation. As discussed, CRSwNP was originally proposed as a distinct phenotype based on the likelihood that it would define a distinct T H 2-high and, more specifically, IL-5-high endotype.
Despite regional differences, up to 85% of NPs can be defined as demonstrating high concentrations of IL-5 (in many but not all regions in the world). 7 This becomes even more complicated with consideration of other cytokines because NPs can also display mixed patterns of expression of IL-5 with concomitant expression of T H 17 (IL-17)-and T H 1 (IFN-g)-associated cytokines. Adding more confusion to these concepts, concentrations of IL-5 extend across a broad continuum in all of these studies, with vast overlap in sinus tissue from those with and without NPs. This promiscuous expression of IL-5 in patients with CRS was further demonstrated when inflammatory endotypes of CRS were studied by using unbiased cluster analyses, in which moderate or high IL-5 expression could be observed in clusters that included or excluded NPs. 10 Finally, it should be emphasized that although early studies suggested that CRSsNP was likely to be a disease with a T H 1 signature, subsequent work demonstrates this tissue is fully capable of expressing profiles associated with T H 1, T H 2, and T H 17 signatures alone or in combination (although with comparatively lower levels of T H 2 cytokines). 7 However, the most common profile is probably that of an innate inflammatory process. 17 All of these observations force consideration that the very concept of their being ''distinct'' endotypes in patients with CRS is misguided; that is, instead of being distinct phenotypes or endotypes defined by the absolute presence or absence of eosinophils, a given cytokine, or of any other specific marker, CRS needs to be approached properly as a continuum of inflammatory processes with high and variable expression of immune and inflammatory markers. Thus, in the case of eosinophilia, in our recently published studies, 18 although it was possible to define a cohort of noneosinophilic NPs (< _3 eosinophils in 10 distinct 3400 high-powered fields) and we could similarly define hypereosinophilic NPs (> _25 eosinophils), the majority of patients fell within a continuum of intermediate expression (Fig 2) 18 without any distinct cutoff that would unambiguously separate an ''eosinophilic'' from a ''noneosinophilic'' process. These data argue that any attempt to define a distinct cutoff distinguishing eosinophilic from noneosinophilic polyps would be at best arbitrary.
This concept is further demonstrated by the study by Wang et al, 7 in which the investigators distinguished CRS with ''high'' from CRS with ''low'' IL-5 levels using a tissue concentration of 1189.10 mg/L. This suggests that a tissue concentration of 1189.09 mg/L would not be an IL-5-driven disease, whereas a tissue concentration of 1189.11 mg/L would, and thereby only at that threshold would consideration of using IL-5 antagonists be entertained. Although accepting the arbitrariness of any specific cutoff being used to define an endotype, it remains reasonable to speculate that more robust expression of any of these markers can serve as an aid for guiding therapeutic decisions. Finally, it is perhaps also important to recognize that in the absence of unambiguous overarching evidence diagnostic of a specific endotype (eg, the rare CF polyp with too many eosinophils to count), none of these markers has proved superior (and certainly not easier to identify) than distinguishing the presence and absence of NPs.
A completely distinct and intriguing endotype of CRS has been described recently based on expression of bitter taste receptors. Studies have described the presence of taste receptors in the airway and more specifically also in the sinonasal mucosa. [19] [20] [21] A specific bitter taste receptor, T2R38, which is localized to the motile cilia, was found to be capable of responding to specific ''quorum-sensing molecules'' produced by gram-negative bacteria, such as Pseudomonas species. In vivo studies show human sinonasal differentiated cells with normal T2R38 levels respond to stimulation with increased nitrous oxide production and increased ciliary beat frequency. Several studies report an increased rate of ''nontasters'' in the CRS population, 22, 23 whereas others have noted that these patients are at increased risk of failed medical treatment of CRS and have a predicted increased need for surgical intervention. 24 Interestingly, Carey et al 25 showed that Staphylococcus aureus-conditioned medium led to an increase in nitrous oxide production in human sinonasal cells through a bitter taste receptor-independent mechanism. Determination of this specific mechanism of action and the Staphylococcus aureusspecific agonist hold promise for additional areas of study into CRS development. Taken together with a potential role of taste receptors in patients with CRS, both areas of study offer the potential yield of novel therapeutic targets independent of antibiotics or corticosteroids.
CURRENT MEDICAL TREATMENTS OF CRS
More information on current medical treatments of CRS can be found in Table II . 
Nasal saline irrigation
Although saline irrigations are not typically used as an isolated treatment for CRS, their utility and benefits both preoperatively and postoperatively are well reported in practice and in the medical literature. [26] [27] [28] In addition to the mechanical clearance of debris and postoperative packing, benefits noted include improved medication delivery, healing outcomes, and mucociliary clearance. [29] [30] [31] Ongoing areas of research include attempts at quantifying the effect of saline irrigation on nasal secretions and determination of the optimal composition and pH of the irrigation. 32, 33 Generally speaking, the benefits, cost, and ease of irrigating the sinus allow for this treatment method to be recommended across the collective umbrella of the CRS population both as an initial adjunct and as a postoperative treatment measure.
Corticosteroids
Both oral and topical glucocorticoids are recognized as effective therapies for CRS and are used widely in most patients. 2, [34] [35] [36] However, the CRS response rate to glucocorticoids reportedly varies from 50% to 80%, [36] [37] [38] with few detailed analyses having been performed to identify the distinguishing features of responders and nonresponders. 39, 40 That a large cohort of patients with CRS are likely to be nonresponders to glucocorticoids is best evinced from the asthma literature, where it is recognized that up to one third of asthmatic patients do not respond to these agents. In asthmatic patients this was already recognized in the late 1950s with a publication showing that the presence of induced sputum eosinophils was essential for defining a cohort in whom systemic steroids would be effective. 41 These observations presumably reflect the therapeutic benefits derived from the ability of corticosteroids to induce eosinophilic apoptosis. More recently, this observation has been consistently confirmed with the understanding that an eosinophil-high T H 2 lymphocyte signature (IL-5-high/IL-13-high) is a prerequisite for steroids to provide clinical benefit. 42, 43 It seems likely that this observation will extend to CRS and, as with this asthma experience, defining the individual endotype will be required to determine the appropriateness of recommending glucocorticoids.
Systemic antibiotics
Microbial resistance to antibiotics continues to increase at alarming rates. [44] [45] [46] Despite routine administration by health care providers, the actual evidence for oral antibiotics in the treatment of CRS remains sparse. Quality double-blind prospective studies are limited, and those that have been performed often involve significant heterogeneity of the patient groups and inconsistent outcome measures. 47, 48 Soler et al 49 examined the literature involving evidence for antibiotic treatment for CRS, including separation of nonmacrolide from macrolide treatment. The authors suggested that short courses, but not courses of longer than 3 weeks, of nonmacrolide treatment remained an option, with the caveat noted that the evidence was sparse and randomized controlled trials should be a research priority. They noted several studies in which macrolide treatment resulted in a reduction in IL-8 levels, with one study demonstrating a significant effect on patients with low IgE levels. 50 Although further investigation into the mechanism of the macrolide effect is recommended, the authors conclude that prolonged macrolide therapy could be considered an optional treatment in patients with CRS, specifically in those with low IgE levels.
A recent Cochrane review by Head et al 51 noted the dearth of evidence of benefit in the literature for oral antibiotic treatment in patients with CRS. The authors concluded that there was sparse quality evidence in support of oral antibiotics in the treatment of CRS, although they acknowledged similarly the limited potential for extended macrolide therapy on quality-of-life outcomes.
Van Zele et al, 52 in a study incorporated by the reviews listed above, compared the effectiveness of either methylprednisolone or doxycycline with that of placebo in patients with significant or recurrent nasal polyposis, demonstrating a similar effect of both treatment arms on decreased polyp size. More recently, the senior authors of that group compared 2 groups of postoperative patients with recurrent CRSwNP. 53 Treatment with doxycycline for 12 weeks in combination with nasal steroids and saline irrigations demonstrated improved validated symptom and computed tomographic (CT) scan scores compared with treatment with nasal steroids and saline alone.
In an interesting take on the role of antibiotic treatment in patients with CRS, G€ unel et al 54 examined the effect of amoxicillin/ clavulanic acid as a non-anti-inflammatory antibiotic in the treatment of eosinophilic CRS. 54 In patients with noneosinophilic CRS, the authors noted improvement in both symptom and CT scores, although there was no change in endoscopic appearance. Interestingly, the eosinophilic CRS group demonstrated improvement in CT scores but no significant improvement in either the symptom score or endoscopy. The authors suggested the findings warrant altering the treatment paradigm and reconsideration of the role of antibiotics in appropriately phenotyped CRS populations.
As the role of microbial infection in patients with CRS becomes further elucidated, the appropriate role of antibiotics in the treatment of the disease will need to be thoroughly re-examined. Well-executed studies that examine the antimicrobial versus anti-inflammatory effect of antibiotics on appropriate CRS subgroups are also needed to determine which patients are appropriate for treatment with a given antibiotic regimen.
Topical antibiotics
The role of topical antibiotics in the recalcitrant population also continues to be an area of controversy. Conceptually, in the postoperative period the sinus cavities are ideally patent, with removal of diseased tissue allowing for increased delivery of medication to the sinonasal mucosa. Despite the best efforts of medical and surgical treatment, some patients can experience return of inflamed mucosa and purulent drainage. Several studies have examined the utility of mupirocin rinses in the treatment of CRS, showing variable results. [55] [56] [57] [58] In general, treatment-associated negative cultures and improvements in endoscopy or quality-oflife scores appear to be short-lived. The lack of robust studies with appropriate follow-up and the variability of the treatment groups have led multiple systemic reviews and guideline groups to not recommend this intervention as either first-line or an appropriate prolonged therapy. 30, [59] [60] [61] [62] Because both the inflammatory pathways and microbiome data are further delineated, however, the ability to individualize topical antibiotic and/or antiinflammatory therapies might warrant re-evaluating their utility.
Surfactants
Given the refractory nature of CRS, other treatments beyond normal saline have been examined. Surfactants are amphiphilic organic compounds that can reduce surface tension, which in the case of CRS is thought to enable treatment and potential prevention of biofilm formation.
Chiu et al 63 found postoperative use of 1% baby shampoo in a postoperative population led to overall improvement in sinus symptom scores, with specific subjective improvements noted with decreased mucus accumulation and decreased postnasal drip. In addition, the experimental group demonstrated improved olfactory scores and endoscopic examinations when compared with control subjects using normal saline.
Desrosiers et al 64 demonstrated in vitro potential of decreasing biofilms with a citric acid/zwitterion surfactant combined with a hydrodebrider. Of concern, however, Valentine et al 65 subsequently demonstrated worsened cilial morphology in sheep models with zwitterion use compared with when only saline was used.
Farag et al 66 compared the postoperative effect of hypertonic saline to surfactant irrigations, demonstrating no significant difference in CRS symptoms. Interestingly, both patient groups reported increased quality of life and olfactory function during the postoperative period, but 20% of the patients reported poor toleration and cessation of the surfactant irrigations in this study. Although currently not recommended as a first-line treatment, as CRS populations are better described and profiled and newer and more tolerable products are developed, it might be found that there is a specific patient population that benefits from use of surfactants.
Manuka honey and other nonantibiotic approaches to dysbiosis in patients with CRS
Given the potential side effects of antibiotic use and the potential for bacterial resistance, nonantibiotic treatments that address dysbiosis remain enticing. Investigations with various probiotics are early but do show promise. Although the therapeutic and medicinal applications of honey were known in antiquity, it has been considered more recently for use in treatment of skin wounds and ulcers. 67, 68 Noted therapeutic properties of honey that could mediate antimicrobial effects include a low pH and high osmotic pressure. 69 In addition, the glucose oxidase in honey produces hydrogen peroxide at levels that are not damaging to tissues but can affect bacterial loads. 70 Manuka honey specifically has been found to contain increased levels of methylglyoxal, a bioactive compound that correlates with its bactericidal properties. 71 Kwakman et al 72 demonstrated in a stepwise neutralization experiment that the antimicrobial properties of honey were related to production of hydrogen peroxide and methylglyoxal, as well as bee defensin-1. Although several studies have attempted to assess the potential role of honey in the treatment of CRS with variable results, they highlight the potential that exists for examination of alternative and naturally occurring therapies that might ultimately provide significant benefit.
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FUTURE TREATMENTS OF CRS
The most intriguing advances in our approach to patients with CRS are being derived from the development of targeted biotherapeutics. Recent studies suggest the potential benefit of biologics in appropriately identified patients with CRS. Of particular interest is the potential use of biologics directed against T H 2 inflammation-associated mediators, including those that target IgE, IL-4/IL-13, and IL-5.
Anti-IgE
Omalizumab is currently US Food and Drug Administration approved for the treatment of treatment-resistant allergenexacerbated asthma and for chronic urticaria. The role of aeroallergen sensitization (specifically allergic rhinitis) in the pathogenesis of CRS is somewhat controversial and beyond the scope of this article. 76 This controversy is driven in part by the recognition that aeroallergens are unlikely to access the sinus cavities. Furthermore, the concept that anatomic obstruction of the sinus ostia secondary to allergic rhinitis or for any other reason has an etiological role in the pathogenesis of CRS is increasingly questioned. However, the recognition that there is a high prevalence of patients with CRS with increased total serum IgE levels and allergic sensitization led to speculation that IgE-targeting therapies might prove efficacious. If not driven by aeroallergen sensitization, this might reflect IgE sensitization to other antigens, such as Staphylococcus species-derived exotoxins, 10, 77 or the concept that this therapy has efficacy in other conditions not associated with aeroallergen sensitization, such as intrinsic asthma and chronic urticaria. In one study this agent was demonstrated to reduce NP size and improve sinus CT scores while also restoring sense of smell, 78 although this was not confirmed in another underpowered study. 79 
Anti-IL-5/IL-5 receptor
Recently, antibodies that target IL-5 have been approved in the United States for the treatment of refractory asthma, and in the near future, it is expected that an anti-IL-5 receptor antibody will become available. Initial studies with IL-5 antagonists in asthmatic patients produced surprisingly disappointing results until it was demonstrated that it was necessary to first identify only those asthmatic patients with a T H 2-high/eosinophil-high phenotype. [80] [81] [82] An interesting observation is that one of the better biomarkers predictive of a response to IL-5 antagonism in asthmatic patients was the concomitant presence of NPs, pointing to the relative ability of NPs to identify a (systemic) T H 2-high/eosinophil-high inflammatory state. 83 Subsequently, IL-5 antagonists have been demonstrated to reduce the frequency of asthma exacerbations, improve lung function and quality of life, and reduce the need for systemic corticosteroids. Although not as well studied as asthma, trials of IL-5 antagonism in patients with CRS have demonstrated reductions in NP size and reduced need for revision surgery. 84, 85 It is important to note that in at least 1 trial of an IL-5 antagonist in patients with CRS, the investigators confirmed the need to demonstrate the presence of an IL-5-high endotype to predict efficacy. 86 
Anti-IL-4/IL-13
Because of their shared use of the IL-4 receptor (IL-4R) a chain, antibodies to IL-4Ra antagonize binding and the biological activity of both IL-4 and IL-13. The anti-IL-4Ra antibody dupilumab recently received US Food and Drug Administration approval for use in patients with refractory atopic dermatitis. This agent is also being studied in asthmatic patents and, as with the IL-5 antagonists, is demonstrated to reduce exacerbation frequency and improve lung function in asthmatic patients with a T H 2-high phenotype. 87 It is unsurprising that IL-13 antagonists might be particularly useful in asthmatic patients with an IL-13-high inflammatory signature, again pointing to the need to identify appropriate patients for these targeted therapies. 88, 89 As with IL-5 antagonists, anti-IL-4Ra therapy also shows promise in patients with T H 2-high/eosinophilhigh CRS, having been shown to reduce NP size and sinus CT scores while also improving sinus symptoms and restoring sense of smell. 90 Other biotherapeutics in patients with CRS Given the similarity of CRS, especially eosinophilic CRS, to (eosinophilic) asthma, it is reasonable to speculate that, as with topical glucocorticoids and currently available biologics, newer agents being developed for asthma might prove to have efficacy in patients with eosinophilic CRS. Current studies emphasize the importance of airway epithelial cells in having a primary pathogenic role in driving T H 2 immune deviation. In particular, the cytokines thymic stromal lymphopoietin, IL-25, and IL-33 are recognized for their ability to interact with T H lymphocytes (IL-25 and IL-33) or dendritic cells (thymic stromal lymphopoietin) to create a milieu in which naive T H lymphocytes will differentiate into T H 2 effector cells. Such a role for epithelially derived IL-33 in driving a type 2 cytokine signature in patients with CRS is increasingly recognized. 91 Perhaps even more important than their role in T H 2 immune deviation is the ability of these cytokines to drive type 2 cytokine production from many other cell types, including mast cells, innate lymphoid cells, resident memory T cells, eosinophils, and others. Biologics targeting these cytokines are currently under investigation in patients with eosinophilic asthma and atopic dermatitis and, as such, show potential promise in patients with eosinophilic CRS. The upstream T H 2 cytokine-inducing transcription factor GATA-3 has shown promise in decreasing the early-and late-phase asthmatic response in patients, which might be of potential use in the T H 2 high population. 92 
CONCLUSION
Treatment of CRS is currently at a potentially exciting crossroad. On the positive side, numerous therapeutics are in development that seem likely to positively affect patients with this condition. The challenge is that these therapies will require targeted individualized treatments based on identifying patients with the relevant endotype. However, given their expense and the unreasonable expectation that a serial ''trial and error'' approach with these costly reagents is plausible, this will require development of practical, efficient, and cost-effective means of identifying and connecting the right patient to the right agent. Despite the challenges inherent to drug development, this might prove even more daunting than developing the drugs. Ultimately, our ability to define appropriate treatment involves appropriate workup, disease classification, and validation of consistent outcome measures.
